RBC Capital Slashes Verrica's Price Target After Third Rejection – What's Next?

© Reuters. RBC Capital Slashes Verrica’s Price Target After Third Rejection – What’s Next?
  • Verrica Pharmaceuticals Inc (: VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval.
  • RBC Capital Markets has downgraded the stock to Sector Perform from Outperform and lowered the price target from $16 to $4.
  • The analysts note that the issues fall outside of the VP-102’s purview. But as per a follow-up call with management, these recurrent offenses highlight the challenges at play with a manufacturing facility that continues to obstruct regulatory approval.
  • VRCA is working with the FDA and Sterling to resolve the deficiency and potentially identify a new manufacturing partner for the resubmission.
  • RBC writes that VRCA plans to file a Type A meeting request by the end of the week and is working with Sterling to present multiple options to FDA to resolve deficiencies expeditiously.
  • Concurrently, the management is exploring alternative suppliers of VP-102’s bulk solution and has identified one non-sterile facility with transfer underway.
  • As per the analysts, the management hinted at January 2023 for resubmission with a 6-month review period as a conservative estimate regarding the timeline.
  • Price Action: VRCA shares are up 63% at $2.06 during the market session on the last check Wednesday.

Latest Ratings for VRCA

Mar 2022 Brookline Capital Initiates Coverage On Buy
Mar 2022 Needham Maintains Buy
Sep 2021 HC Wainwright & Co. Maintains Buy

View More Analyst Ratings for VRCA

View the Latest Analyst Ratings

© 2022 Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.